Defence Therapeutics

We have achieved a major milestone. Defence Therapeutics Inc. has received a No Objection Letter from Health Canada | Santé Canada to proceed with our Phase I trial of ACCUM-002 (AccuTOX) as a potential anti-cancer treatment for patients with melanoma. The proposed study will ensure patient safety and lead to new effective cancer therapies. We look forward to entering this next phase of our research! Stay tuned for more updates as we move forward with this important clinical trial. Learn more here: https://lnkd.in/e_RQesqT #HealthCanada #ClinicalTrial #CancerResearch #Melanoma #Biotech #Innovation

The project will focus on developing new variations of In-AccuTOX®-Trastuzumab, a potential game-changer in the fight against HER2-positive cancers. Find out more below ⬇

Thank you for sharing the news Health Europa

📢 Big News! Defence Therapeutics has received the CNRI-H grant from Canadian Nuclear Laboratories (CNL) to accelerate our Radio-Immuno-Conjugates Program. Stay tuned for more updates! Learn more here: https://lnkd.in/gKPZwxFm #DefenceTherapeutics #Innovation #Biotech #Research #MedicalAdvancements

For this groundbreaking study, lead researcher Dr. Moutih Rafei مطيع الرافعي from Université de Montréal teamed up with his colleagues at Defence Therapeutics to boost the effectiveness of cancer vaccines. By leveraging MSCs as APCs, they successfully revamped the Accum® technology, originally designed to enhance drug delivery for effective intracellular accumulation. Learn more here. https://lnkd.in/dK4uCWru

We are pleased to announce that our Accum-002TM ("AccuTOX®") has demonstrated dual modes of action. AccuTOX® acts as both a tumor-killing molecule and an immune booster. Its unique mechanism synergizes with the activity of Immune Checkpoint Inhibitors ("ICI") and enhances the immune system's response. 👉 Discover more about this development and its potential impact on cancer treatment. https://lnkd.in/dsf87efq #DefenceTherapeutics #CancerResearch #Immunotherapy #Innovation

Defence Therapeutics receives a no objection letter from Health Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients with melanoma. 💉

Wir haben einen bedeutenden Meilenstein erreicht. Defence Therapeutics Inc. hat von Health Canada | Santé Canada ein No Objection Letter erhalten, um mit unserer Phase-I-Studie von ACCUM-002 (AccuTOX) als potenzielle Krebstherapie für Patienten mit Melanom fortzufahren. Die vorgeschlagene Studie wird die Patientensicherheit gewährleisten und zu neuen wirksamen Krebstherapien führen. Wir freuen uns darauf, in die nächste Phase unserer Forschung einzutreten! Bleiben Sie dran für weitere Updates, während wir mit dieser wichtigen klinischen Studie voranschreiten. https://lnkd.in/e_RQesqT #HealthCanada #ClinicalTrial #CancerResearch #Melanoma #Biotech #Innovation

Nous avons atteint une étape majeure. Defence Therapeutics Inc. a reçu une lettre de non-objection de Health Canada | Santé Canada pour procéder à notre essai de phase I de l'ACCUM-002 (AccuTOX) en tant que traitement potentiel contre le cancer pour les patients atteints de mélanome. L'étude proposée garantira la sécurité des patients et ouvrira la voie à de nouvelles thérapies efficaces contre le cancer. Nous sommes impatients d'entrer dans cette prochaine phase de notre recherche! Restez à l'affût pour plus de mises à jour à mesure que nous avançons avec cet essai clinique important. En savoir plus: https://lnkd.in/e_RQesqT #SantéCanada #EssaiClinique #Mélanome #Biotech #Innovation

Another published paper! This time we present AccuTOX®; an injectable anti-cancer molecule granted clearance by the FDA in 2023 for a Phase I trial (currently under preparation by Defence Therapeutics). Background: The Accum® platform was initially designed to accumulate biomedicines in target cells by inducing endosomal-to-cytosol escape. Interestingly however, the use of unconjugated Accum® was observed to trigger cell death in a variety of cancer cell lines; a property further exploited in the development of Accum®-based anti-cancer therapies. Despite the impressive pro-killing abilities of the parent molecule, some cancer cell lines exhibited resistance. This prompted us to test additional Accum® variants, which led to the identification of the AccuTOX® molecule. This study reveals the potency and MoA of AccuTOX® where we demonstrate how the molecule exhibits enhanced cancer killing properties, retains all the innate characteristics displayed by the parental Accum® molecule, and synergizes with various immune-checkpoint inhibitors in controlling tumor growth. These observations will certainly pave the path to continue the clinical development of this lead compound against multiple solid tumor indications.